12:00 AM
Jan 02, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Multaq dronedarone regulatory update

FDA completed a safety review of Sanofi's Multaq dronedarone and recommended against use of Multaq dronedarone to treat permanent atrial fibrillation (AF). The agency said the review showed the multichannel blocker with properties of antiarrhythmics in Vaughan-Williams classes I-IV increased the risk of serious...

Read the full 197 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >